SCHEMBL21552142

SCHEMBL21552142

CN(CCCSc1cccc(Br)c1)C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
KMT2A Q03164 3/20 0.47
MAPT P10636 3/20 0.47
KDM4E B2RXH2 3/20 0.46
LMNA P02545 2/20 0.46
POLB P06746 1/20 0.43
MAOA P21397 1/20 0.42
HSP90AA1 P07900 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
FDPS P14324 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
TMEM97 Q5BJF2 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
MEN1 O00255 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24591933 0.82 ALDH1A1 (0.39) ALDH1A1KMT2AMAPTKDM4ELMNA
SCHEMBL29647894 0.82 ALDH1A1 (0.39) ALDH1A1KMT2AMAPTKDM4ELMNA
SCHEMBL6191672 0.78 ALDH1A1 (0.67) ALDH1A1KMT2AMAPTKDM4ELMNA
SCHEMBL21569870 0.77 MAOA (0.44) ALDH1A1KMT2AMAPTKDM4ELMNA
SCHEMBL17364189 0.77 MAOA (0.55) ALDH1A1MAOAHSP90AA1RXFP1HDAC3
SCHEMBL5447638 0.74 ALDH1A1 (0.51) ALDH1A1KMT2AMAPTKDM4ELMNA
SCHEMBL7015925 0.74 RAB9A (0.47) ALDH1A1KMT2AKDM4ELMNAFDPS
SCHEMBL1369409 0.74 MAOA (0.49) ALDH1A1KMT2AMAPTMAOAHSP90AA1
SCHEMBL1710914 0.74 MAOA (0.53) ALDH1A1MAPTMAOAHSP90AA1RXFP1
SCHEMBL671196 0.73 MAOA (0.49) ALDH1A1KMT2AMAPTLMNAMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230079407-A1 ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF REGENERON PHARMACEUTICALS, INC. 2023-03-16 US disclosed
US-11377502-B2 Anti-MSR1 antibodies and methods of use thereof REGENERON PHARMACEUTICALS, INC. (US) 2022-07-05 US disclosed
EP-3790899-A1 ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2021-03-17 EP disclosed
WO-2019217591-A1 ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2019-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079407-A1 ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF CD47, MSR1, LDLR ALDH1A1 3728/4885KMT2A 710/4885MAPT 4571/4885
US-11377502-B2 Anti-MSR1 antibodies and methods of use thereof CD47, MSR1, LDLR ALDH1A1 3728/4885KMT2A 710/4885MAPT 4571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.